Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FluBHPVE6E7 in HPV-16 infected women with normal cytology, CIN1 or CIN2
NCT04490512Phase 1Completed
- Sponsor
- BlueSky Immunotherapies
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FluBHPVE6E7 in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) (4 arms), sponsored by BlueSky Immunotherapies. Primary endpoint: Number of participants with adverse events at 16 weeks. Started Dec 2020; status: completed.
02
Drugs
FluBHPVE6E7
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT04490512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04490512.